The purpose of this multicenter, prospective, group-controlled cancer screening study is to evaluate whether a new blood test is suitable to distinguish malignant tumors (cancers) from other tumors/diseases and control subjects.
The AFORCE-1 study aims to test the accuracy of this blood test before it can later be used in diagnostics. Patients with suspected tumors (10 most common tumor types) and healthy volunteers are included in the study. The development of the suspected tumor will be monitored over a period of 12 months and compared with the result of the blood test for early cancer detection at the end of the study.
The study was positively evaluated by the Colorectal Cancer Study Board of the German Cancer Society on 05.04.2024. It thus fulfills the criteria for recognition of the study within the certification system and is listed in studybox(www.studybox.de). The registration number is: ST-U178.